Tirzepatide (Zepbound / Mounjaro) in Chicago

Typical Tirzepatide (Zepbound / Mounjaro) pricing in Chicago runs $300–$1,100 per month. The biggest variables are the provider's experience level and the specific device or product used — newer technology and senior injectors price at the upper end. Pricing is quoted in US dollars (USD). Request a consultation from any of our listed Chicago clinics for a personalized quote.

ClinicCompass lists 9 verified Chicago-area clinics offering Tirzepatide (Zepbound / Mounjaro), concentrated in Chicago. Each listing includes real Google ratings so you can compare reputable options side by side before booking a consultation.

Among our 9 listed Chicago providers for Tirzepatide (Zepbound / Mounjaro), Essex Skin Medical Aesthetics currently holds the highest verified Google rating at 5★ across 109+ reviews (located in Chicago). "Best" is subjective — compare 2–3 Chicago clinics before committing.

Results vary by patient, but most Chicago providers report 6–18 months of sustained benefit from a full Tirzepatide (Zepbound / Mounjaro) series.

Most patients wait 24 hours before applying makeup to avoid irritation on freshly-treated skin.

Same drug — tirzepatide — different approvals. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for weight loss and obstructive sleep apnea. Weight-loss patients paying cash usually end up with Zepbound, which the manufacturer also sells directly in lower-cost single-dose vials.

On trial averages, yes. SURMOUNT-1 showed ~20–22% average body weight loss at the top dose, and the head-to-head SURMOUNT-5 trial (2025) found tirzepatide patients lost meaningfully more than semaglutide patients (~20% vs ~14%). Averages aren't individuals — plenty of people do great on semaglutide — but if maximum medication effect is the goal, tirzepatide is the current benchmark.

Zepbound lists around $1,100/month, but the manufacturer's direct-to-patient vial program cut cash prices to roughly $349–$499/month depending on dose. Clinic and med spa programs using pharmacy-prepared tirzepatide have typically charged $300–$600/month with supervision included. As with semaglutide, compounding rules tightened after the FDA shortage designation ended — ask exactly what's being dispensed.

Very similar profile to semaglutide: nausea during dose escalation, constipation or diarrhea, fatigue, reflux. Some patients tolerate tirzepatide's dual mechanism a bit better; others notice no difference. The serious-but-rare list is the same — pancreatitis, gallbladder issues — and the same thyroid-cancer-history exclusions apply. Rapid weight loss also means facial volume loss ('Ozempic face' applies here too), which many patients address with fillers or Sculptra.

The SURMOUNT-4 withdrawal study answered this directly: patients who stopped tirzepatide regained about half the lost weight within a year, while those who continued kept losing. Like all GLP-1s, it's a long-term commitment — plan the maintenance strategy up front.

Consider tirzepatide if: you want the strongest average results, you tried semaglutide with underwhelming effect, or cash price via the manufacturer's vial program beats your semaglutide options. Consider semaglutide if: your insurance covers Wegovy, you want the longest safety track record, or your provider's semaglutide program is meaningfully cheaper. Both beat every weight-loss medication that came before them.